1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Oxaliplatin Powder for Injection

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family:</td>
<td>Not determined</td>
</tr>
<tr>
<td>Intended Use:</td>
<td>Pharmaceutical product used as Antineoplastic</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance: White lyophilised cake
Signal Word: DANGER

Statement of Hazard:
May damage the unborn child.
May cause genetic defects.

Additional Hazard Information:

Short Term:
Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions.

Long Term:
Repeat-dose studies in animals have shown a potential to cause adverse effects on testes and the developing fetus. May cause effects on blood and blood forming organs.

Known Clinical Effects:
Adverse effects most commonly reported in clinical use include vomiting nausea diarrhea bone marrow suppression decreased red blood cell count (anemia) decreased white blood cells (leukopenia) decrease in platelets and red/white blood cells (pancytopenia) nervous system/brain toxicity (neurotoxicity) and skin and acute mucous membrane irritation.

EU Classification
EU Indication of danger: Toxic to Reproduction: Category 2
Mutagenic: Category 2

EU Hazard Symbols:

EU Risk Phrases:
R61 - May cause harm to the unborn child.
R46 - May cause heritable genetic damage.
2. HAZARDS IDENTIFICATION


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxaliplatin</td>
<td>61825-94-3</td>
<td>Not Listed</td>
<td>Repr. Cat.2,R61; Muta. Cat.2,R46</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
</table>
| Lactose NF, monohydrate | 64044-51-5 | Not Listed            | Not Listed        | * | Additional Information: * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.
6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Oxaliplatin

| Pfizer Occupational Exposure Band (OEB): | OEB 4 (control exposure to the range of 1ug/m³ to <10ug/m³) |

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

| Hands: | Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations. |
| Eyes: | Wear safety glasses or goggles if eye contact is possible. |
| Skin: | Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. |
| Respiratory protection: | If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range. |
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>lyophilised cake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Color:</td>
<td>White</td>
</tr>
<tr>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

| Chemical Stability: | Stable under normal conditions of use. |
| Conditions to Avoid: | Fine particles (such as dust and mists) may fuel fires/explosions. |
| Incompatible Materials: | As a precautionary measure, keep away from strong oxidizers |

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient

Acute Toxicity: (Species, Route, End Point, Dose)

- **Oxaliplatin**
  - **Rat**  Oral  **LD50 > 100 mg/kg**

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

- **Oxaliplatin**
  - **Eye Irritation (In vitro, BCOP)** Irritant
  - **Skin Irritation (In vitro, RhE)** Negative

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

- **Oxaliplatin**
  - **Fertility and Embryonic Development**  **Rat**  No route specified  **1 mg/kg/day**  NOAEL  Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

- **Oxaliplatin**
  - **Bacterial Mutagenicity (Ames)**  **Salmonella** Negative
  - **In Vitro Mammalian Cell Mutagenicity**  **Mouse Lymphoma** Positive
  - **In Vitro Chromosome Aberration**  **Human Lymphocytes** Positive
  - **In Vivo Micronucleus**  **Mouse Bone Marrow** Positive

Carcinogen Status: Not listed as a carcinogen by IARC, NTP or US OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic to Reproduction: Category 2
Mutagenic: Category 2

EU Risk Phrases:
R61 - May cause harm to the unborn child.
R46 - May cause heritable genetic damage.

EU Safety Phrases:
S22 - Do not breathe dust.
S53 - Avoid exposure - obtain special instructions before use.
S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:
DANGER
May damage the unborn child.
May cause genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision B
15. REGULATORY INFORMATION

Lactose NF, monohydrate
  Australia (AICS): Present

Oxaliplatin
  Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R46 - May cause heritable genetic damage.
R61 - May cause harm to the unborn child.

Data Sources: Publicly available toxicity information.

Prepared by: Product Stewardship Hazard Communication
  Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet